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Abstract. This study examined whether the anticholiner- 
gic potency of the clinically superior antipsychotic drug 
clozapine contributes to clozapine's anatomically-selec- 
tive functional inhibition of the mesolimbic dopamine 
(DA) system, using an electrical brain-stimulation re- 
ward (BSR) paradigm in rats that has been previously 
shown to be highly sensitive to clozapine's mesolimbic 
functional selectivity. Rats were chronically administered 
saline, clozapine, haloperidol, or haloperidol plus the 
anticholinergic compound trihexyphenidyl, and thresh- 
old sensitivity of the mesolimbic and nigrostriatal DA 
systems was assessed using the BSR paradigm, to infer 
degree of functional DA blockade produced by the 
chronic drug regimens. Chronic saline produced no 
change in either DA system. Congruent with previous 
findings, chronic clozapine powerfully inhibited the 
mesolimbic DA system but spared the nigrostriatal DA 
system. Also congruent with previous findings, chronic 
haloperidol powerfully inhibited both DA systems. Com- 
pared to chronic haloperidol alone, chronic haloperidol 
plus chronic trihexyphenidyl exerted diminished anti-DA 
action in both the mesolimbic and nigrostriatal DA sys- 
tems. These results suggest that clozapine's anticholiner- 
gic potency is not an adequate explanation for its func- 
tional mesolimbic selectivity. 
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The antipsychotic drug clozapine is remarkable. It is a 
superior antipsychotic agent, with proven therapeutic 
efficacy for even neuroleptic-resistant schizophrenia 
(Kane et al. 1988; Meltzer et al. 1989a; Gerlach 1991; 
Kane 1992). It is also virtually devoid of propensity to 
induce extrapyramidal side effects and tardive dyskinesia 
(Casey 1989; Meltzer et al. 1989a; Gerlach 1991; Jann 
1991; Kane 1992). The neuropharmacological mecha- 
nisms underlying this unusual clinical profile are unclear 
(Coward et al. 1989; Meltzer et al. 1989a; Gerlach 1991 ; 
Jann 1991). While clozapine's interaction with classically 
defined brain dopamine (DA) receptors (i.e., DI and D2) 
is weak, studies of presynaptic DA neural function rather 
than postsynaptic DA receptor occupancy (e.g., behav- 
ioral, electrophysiological recording, electrical brain 
stimulation, in vivo brain microdialysis, and in vivo brain 
electrochemistry studies) show that clozapine powerfully 
inhibits mesolimbic DA function while sparing nigro- 
striatal DA function (Huff and Adams 1980; Chiodo and 
Bunney 1983; White and Wang 1983; Hand et al. 1987; 
Gardner and Seeger 1988; Chen et al. 1991; Gardner 
1992a). This selective action on the mesolimbic system 
may partly account for clozapine's atypical clinical 
profile, since the antipsychotic efficacy of neuroleptics is 
widely presumed to derive from suppressive action on the 
mesolimbic DA system (Stevens 1979, Creese 1983) while 
their extrapyramidal side effects are presumed to derive 
from suppressive action on the nigrostriatal DA system 
(Creese 1983; Baldessarini 1985). 
Clozapine affects many brain transmitter systems 
(Meltzer et al. 1989a; Gerlach 1991; Jann 1991), but 
which of clozapine's neuropharmacological actions im- 
parts its anatomically selective functional antagonism of 
the mesolimbic DA system is obscure. Suggestions have 
included clozapine's serotonergic blockade (Meltzer et al. 
1989a; Chen et al. 1992b), noradrenergic blockade 
(Chiodo and Bunney 1985), preferential blockade of D1 
versus D2 receptors (Coward et al. 1989), combined 
blockade of D1 and  D2 receptors (Farde et al. 1989), 
interaction with a new subtype of DA receptor (van Tol 
et al. 1991), and production of specific ratios of blockade 
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between multiple neurotransmitter  systems (Meltzer et 
al. 1989b). Recently, two groups (Chiodo and Bunney 
1985; Lane and Blaha 1986) have reported that, in rats, 
the addition of  an anticholinergic to the typical neurolep- 
tic haloperidol changes haloperidol 's  nonselective func- 
tional inhibition of  both  the mesolimbic and nigrostriatal 
DA systems into an anatomically selective inhibition of  
the mesolimbic D A  system resembling that of  clozapine. 
Since clozapine is potently anticholinergic (Bolden et al. 
1992), such findings have initial appeal. However,  they 
appear  at variance with the observations that:  1) addi- 
tion of  anticholinergics to neuroleptic medication de- 
tracts f rom antipsychotic efficacy rather than producing 
the superior antipsychotic effects ofclozapine (Singh and 
Kay  1979; Johnstone et al. 1983), and 2) anticholinergic 
medications do not reduce the risk of  tardive dyskinesia 
after long-term neuroleptic exposure (Klawans 1973) and 
can even exacerbate existing tardive dyskinesia (Bal- 
dessarini and Tarsy 1979) rather than producing the 
suppression of  tardive dyskinesia seen with clozapine 
(Casey 1989; Kane  1992). 
We have previously adapted the paradigm of  electrical 
brain-stimulation reward (BSR) as an anatomically spe- 
cific probe of  functional D A  activation or inhibition in 
the mesolimbic and nigrostriatal D A  systems. This ap- 
proach rests upon the coincidence that portions of  the 
mesolimbic and nigrostriatal D A  systems of  the mam-  
malian brain are involved in mediating direct brain re- 
ward (Wise and Rompre  1989; Gardner  1992b). Using 
the BSR paradigm, we and others have found that  chron- 
ic D A  antagonist  administration produces robust  and 
prolonged functional D A  upregu!ation following an- 
tagonist cessation, reflecting a rebound functional D A  
supersensitivity (Ettenberg and Milner 1977; Seeger and 
Gardner  1979; Seeger et al. 1981). This paradigm is 
highly sensitive to the functional D A  blockade produced 
by antipsychotic drugs, and to antipsychotic drug dose 
(Seeger and Gardner  1979; Seeger et al. 1981; Gardner  
and Seeger 1988; Gardner  1992a). Using this paradigm 
in animals with electrodes implanted into mesolimbic 
and nigrostriatal D A  loci, we have previously reported 
that BSR is highly sensitive to the mesolimbically-selec- 
tive functional DA antagonism produced by clozapine 
(Gardner  and Seeger 1988; Gardner  1992a). Specifically, 
in animals with electrodes implanted in the mesolimbic 
system, both haloperidol and clozapine (in chronic doses 
equated for antischizophrenic efficacy) produced highly 
significant (and equivalent) BSR enhancement following 
chronic treatment.  In animals implanted with electrodes 
in the nigrostriatal system, only haloperidol produced 
BSR enhancement following chronic treatment,  while 
clozapine's effects were indistinguishable f rom those of  
chronic saline (Gardner  and Seeger 1988; Gardner  
1992a). 
Given this utility of  the BSR paradigm to detect 
clozapine's mesolimbically-selective action, the present 
study was undertaken to determine whether the addition 
of the potent  anticholinergic compound  trihexyphenidyl 
to a regimen of  chronic haloperidol would shift halo- 
peridol 's non-selective functional blockade of both  the 
mesolimbic and nigrostriatal D A  systems to a meso- 
limbically selective functional DA blockade resembling 
that of  clozapine. 
Materials and methods 
Forty male Sprague-Dawley rats (Taconic) weighing between 200 
and 225 g at the start of experimentation were used, They were 
housed individually on ad libitum food and water in an animal 
colony room kept at 22 ° C with a 12 h light-dark cycle. Rats were 
randomly assigned to the following four chronic drug groups: 
saline, clozapine, haloperidol, and haloperidol plus trihexyphenidyl. 
The rats were then anesthetized with sodium pentobarbital 
(50 mg/kg) and surgically implanted, using standard stereotaxic 
procedures, with chronic bipolar intracranial BSR electrodes (Plas- 
tic Products type MS303/1). Half of the animals in each drug group 
were implanted with electrodes in the ventral tegmental area (DA 
nucleus A10; mesolimbic DA cell bodies of origin) at stereotaxic 
coordinates AP + 2.8, L 1.2, H -3.5, according to the rat brain 
stereotaxic atlas of Pellegrino et al_ (1979). The other half of each 
drug group were implanted with electrodes in the substantia nigra 
(DA nucleus A9; nigrostriatal DA cell bodies of origin) at stereo- 
taxic coordinates AP + 2.8, L 2.3, H -2.8 (Pellegrino et al. 1979). 
The animals were allowed 10 days recovery from surgery and were 
then trained to self-administer BSR electrical stimulation through 
the implanted electrodes using methods we have previously de- 
scribed (Gardner et al. 1988). Training and testing was carried out 
in standard operant chambers equipped with two response levers. 
Microprocessor/brain-stimulator units were programmed to deliver 
titrating threshold decremental brain stimulation. Each response by 
the animal on the primary lever delivered a 250 ms stimulus train 
(60 Hz bipolar rectangular pulse-pairs of 0.3 ms duration, with a 
0.15 ms delay between the pulses of each balanced pair of opposite 
polarity) through the brain electrode. Initial current intensity was 
assigned to each animal at the lowest intensity supporting reliable 
responding at a rate of 650 lever presses per 20-min test session. 
Training was initiated using continuous (fixed ratio 1: 1) BSR rein- 
forcement on the primary lever. This was followed by training 
sessions in which first one lever and then the other was active, to 
induce the rats to alternate between levers to seek the stimulus- 
active lever. After proficiency and high stable rates of responding 
were achieved at this task, the animals were switched to the final 
BSR threshold titration paradigm. For this, the primary lever was 
fixed as the only lever delivering BSR, and the previously assigned 
stimulation current level for each individual rat was set as the 
maximum level of a descending series of current intensity steps for 
that animal. The BSR current decremented by 1/16 of this maxi- 
mum intensity at every third press of the primary lever. At any time 
during the ensuing sequence of BSR stimuli of decreasing mag- 
nitude, the animal could reset the current to its individually-as- 
signed maximum by pressing the second or "reset" lever, which reset 
the brain stimulation back to maximum for that animal and also 
activated a cue-signal tone but did not itself deliver brain stimula- 
tion. The current steps at which each animal reset were automatically 
recorded throughout each 20-rain test session, and the mean of the 
resulting frequency distribution of reset levels was operationally 
defined as the BSR threshold. The standard deviation of this fre- 
quency distribution was taken as a measure of performance stabil- 
ity, with a standard deviation of 3:1.5 current steps used as the 
criterion for stable performance and inclusion in the drug study. 
Brain stimulation threshold data were collected and analyzed by 
on-line microprocessor units. After training to stable performance, 
each animal was tested daily for a minimum of 6 weeks to ensure 
an absolutely stable baseline of BSR thresholds before drug trials 
began. 
The drugs and amounts used were: haloperidol, 1.0 mg/kg/day; 
clozapine, 20.0 mg/kg/day; trihexyphenidyl hydrochloride, 1.0 rag/ 
kg/day; saline, 0.4 ml/day. The clozapine was dissolved in dilute 
hydrochloric acid and adjusted to pH 3.5 with sodium bicarbonate. 
The clozapine dose was chosen by a comprehensive survey of 
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clozapine use, both clinically and in electrophysiological, biochemi- 
cal, and behavioral laboratory paradigms. The haloperidol dose 
was similarly chosen. These are the same doses used in our previous 
studies of clozapine's functional mesolimbic DA selectivity (Seeger 
and Gardner 1979; Seeger et al. 1981; Gardner and Seeger 1988; 
Chen et al. 1991 ; Chen et al. 1992a,b; Gardner 1992a). The 20:1 
dose ratio between clozapine and haloperidol also reflects the ap- 
proximate clinical ratio needed for equivalent control of schizo- 
phrenia (Seeman 1987); it is also the same dose ratio used by other 
groups studying clozapine's mesolimbic selectivity (Chiodo and 
Bunney 1985). Trihexyphenidyl's anticholinergic profile resembles 
that of clozapine (Bolden et al. 1992). The trihexyphenidyl dose was 
chosen as representing a clinically meaningful ratio to the haloperi- 
dol dose, and is the same dose used by Chiodo and Bunney (1985) 
and Lane and Blaha (1986) in their studies of anticholinergic 
involvement in clozapine's mesolimbic selectivity. 
After the 6-week BSR stabilization period, pre-drug baseline 
BSR threshold level was determined for each rat on three consecu- 
tive days, after which each rat was given the drug treatment (by 
intraperitoneal injection, once daily at 4:00 pm for 3 weeks) corre- 
sponding to its assigned group (clozapine, haloperidol, haloperidol 
plus trihexyphenidyl, saline). We have previously shown that 3 
weeks of daily antipsychotic treatment yields maximal functional 
DA upregulation in the BSR paradigm (Seeger and Gardner 1979; 
Seeger et al. 1981 ; Gardner and Seeger 1988; Gardner 1992a). After 
the chronic drug treatment, rats were given 3 days of drug washout, 
and then retested in the BSR paradigm for drug-induced functional 
hypersensitivity in the mesolimbic or nigrostriatal DA system at 3, 
5, 7, 10, 13, 16, 19, 22, 25, 28, and 32 days following termination 
of drug treatment. Significance of shifts in BSR threshold between 
predrug and postdrug test sessions, and between drug groups, was 
analyzed by analysis of variance (ANOVA) for repeated measures 
(Kirk 1982), with individual comparisons within each data set tested 
for significance by the Tukey-Kramer a posteriori statistical 
procedure (Kirk 1982). 
At the end of the study, all animals were killed by anesthetic 
overdose, the brains removed, and standard histology carried out 
to confirm the brain locations of the BSR electrodes. 
Results 
Three  weeks o f  saline had  no effect on BSR thresholds  
f r o m  electrodes in ei ther the meso l imbic  or  nigrost r ia ta l  
D A  systems. In  an imals  with meso l imbic  electrodes,  both 
chronic  ha loper ido l  and chronic  c lozapine p roduced  sig- 
nificantly lower BSR thresholds  fol lowing cessat ion o f  
ant ipsychot ic  drug  t r ea tmen t  ( A N O V A  for  repeated  
measures :  ma in  drugs  effect - Fz,11 = 8.2, P < 0 . 0 1  ; ma in  
test sessions effect - Fio,110 = 88.2, P < 0 . 0 0 0 1  ; drugs  x 
test sessions in terac t ion  - F2o.1~o = 12.5, P < 0 . 0 0 0 1 ) .  In  
these mesol imbica l ly  implan ted  animals ,  individual  com-  
par isons  showed tha t  BSR thresholds  fol lowing both 
chronic  ha loper ido l  and chronic  c lozapine were signifi- 
cant ly  enhanced  as c o m p a r e d  to BSR thresholds  follow- 
ing chronic  saline for  days  3, 5, 7, 10, 13, and  16 af ter  
cessat ion o f  drug  t rea tment .  
In  an imals  with n igros t r ia ta l  electrodes,  only chronic  
ha loper ido l  p roduced  significantly lowered BSR thresh- 
olds fol lowing cessat ion o f  an t ipsychot ic  d rug  t r ea tmen t  
( A N O V A  for  repeated  measures :  ma in  drugs effect - 
F2,10=7.8,  P < 0 . 0 1 ;  ma in  test sessions effect 
F lo joo  = 17.2, P < 0 . 0 0 0 1 ;  drugs  x test sessions interac-  
t i o n -  F 2 o , t o 0 = l l . 4 ,  P < 0 . 0 0 0 1 ) .  I n ' t h e  nigrost r ia ta l  
system, the effect o f  chronic  c lozapine was  no different 
f r o m  tha t  o f  saline. Ind iv idua l  compar i sons  o f  the da ta  
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Fig. 1. Effects of 3 weeks of chronic daily treatment with saline (o), 
clozapine (20 mg/kg/day) (v), and haloperidol (1 mg/kg/day) (D) 
on post-chronic-treatment DA functional upregulation in the 
mesolimbic and nigrostriatal DA systems, as assessed by electrical 
brain-stimulation reward thresholds in laboratory rats. Decreases 
in brain reward threshold (i.e., data points significantly below the 
100% baseline) represent enhanced DA functional upregulation 
following cessation of chronic drug treatment, implying functional 
DA antagonism during chronic drug treatment (see text). The statis- 
tically significant individual comparisons noted on the figure by ?% 
**, #, and ## were calculated using the Tukey-Kramer a posteriori 
statistic, following overall statistically significant ANOVAs for 
repeated measures (see text) 
f rom nigros t r ia ta l ly- implanted  an imals  showed tha t  BSR 
thresholds  fol lowing chronic  ha loper idol  were signifi- 
cant ly  enhanced as compa red  to BSR thresholds following 
both chronic  saline and chronic  clozapine for  days 3, 5, 7, 
10, 13 and  for  days 3, 5, 7, 10, respectively, after  cessation 
of  drug  t reatment .  BSR thresholds following chronic 
clozapine were not  significantly different f rom BSR 
thresholds following chronic  saline a t  any  point.  These 
findings are illustrated in Fig. 1. 
The  addi t ion  o f  t r ihexyphenidyl  to ha loper idol  de- 
tracted f r o m  ha loper ido l ' s  po tency  in both the mesol im-  
bic and nigrost r ia ta l  systems. In  aminals  with mesol imbic  
electrodes,  chronic  ha loper ido l  p roduced  significantly 
lower BSR thresholds  fol lowing cessat ion o f  anti-  
psychot ic  drug  t r ea tmen t  than  did the chronic  haloper i -  
dol plus t r ihexyphenidyl  regimen,  but  the ha loper idol  
plus t r ihexyphenidyl  did not  significantly lower BSR 
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Fig. 2. Effects of 3 weeks of chronic daily treatment with saline (o), 
haloperidol (1 mg/kg/day) ([]), and haloperidol-plus-trihexyphenidyl 
(1 mg/kg/day plus 1 mg/kg/day) (*) on post-chronic-treatment DA 
functional upregulation in the mesolimbic and nigrostriatal DA 
systems, as assessed by electrical brain-stimNation reward 
thresholds in laboratory rats. Decreases in brain reward threshold 
(i.e., data points significantly below the 100% baseline) represent 
enhanced DA functional upregulation following cessation of chron- 
ic drug treatment, implying functional DA antagonism during 
chronic drug treatment (see text). The statistically significant in- 
dividual comparisons noted on the figure by t, *, and ** were 
calculated using the Tukey-Kramer a posteriori statistic, following 
overall statistically significant ANOVAs for repeated measures (see 
text). The saline and haloperidol groups shown here are the same 
animals as shown for those groups in Fig. 1 
treatment as compared to saline (overall ANOVA for 
repeated measures: main drugs effect - F242=9.1, 
P<0.005;  main test sessions effect - F~o42o=31.7, 
P<0.0001;  drugs x test sessions interaction - 
F2o,12o = 10.3, P <  0.0001). In these mesolimbically im- 
planted animals, individual comparisons showed that 
BSR thresholds following chronic haloperidol were sig- 
nificantly enhanced as compared to BSR thresholds fol- 
lowing chronic haloperidol plus trihexyphenidyl for days 
3, 5, 7, 10, and 13 after cessation of drug treatment. 
BSR thresholds following chronic haloperidol plus 
trihexyphenidyl were not significantly different from 
BSR thresholds following chronic saline at any point, 
except for the first 2 days after cessation of antipsychotic 
drug treatment. Similarly, in animals with nigrostriatal 
electrodes, chronic haloperidol produced significantly 
lower BSR thresholds following cessation of anti- 
psychotic drug treatment than did the chronic halo- 
peridol plus trihexyphenidyl regimen, but the chronic 
haloperidol plus trihexyphenidyl combination did not 
significantly lower BSR thresholds following cessation of 
antipsychotic drug treatment as compared to saline 
(overall ANOVA for repeated measures: main drugs effect 
- F2xo= l l . 9 ,  P<0.005;  main test sessions effect - 
Flo,loo = 14.6, P<0.0001;  drugs x test sessions interac- 
tion - Fzo,loo=4.4, P <  0.0001). In these nigrostriatally 
implanted animals, individual comparisons showed that 
BSR thresholds following chronic haloperidol were sig- 
nificantly enhanced as compared to BSR thresholds fol- 
lowing chronic haloperidol plus trihexyphenidyl for days 
3, 7, 10, 13, and 16 after cessation of drug treatment. BSR 
thresholds following chronic haloperidol plus trihexy- 
phenidyl were not significantly different from BSR 
thresholds following chronic saline at any point. These 
findings are illustrated in Fig. 2. 
Discussion 
The present findings suggest several things. First, they 
confirm the notable mesolimbic anatomic selectivity of 
clozapine's functional DA blockade. Chronic neuroleptic 
treatment is well known to produce DA functional upreg- 
ulation following cessation of neuroleptic treatment, 
similar to the DA denervation supersensitivity seen after 
lesions of central DA pathways (Ungerstedt 1971; Heal 
et al. 1976). The BSR paradigm is a sensitive assay of this 
DA functional upregulation following chronic neurolep- 
tic treatment (Ertenberg and Milner 1977; Seeger and 
Gardner 1979; Seeger et al. 1981), from which it is in- 
ferred that functional DA blockade occurred during the 
neuroleptic treatment. Also, the BSR paradigm is sen- 
sitive to clozapine's anatomically selective functional 
blockade of the mesolimbic DA system (Gardner and 
Seeger 1988; Gardner 1992a). The present data thus 
agree with such previous BSR studies, and also agree 
with studies of clozapine's mesolimbically selective DA 
blockade using other paradigms (e.g., Huff and Adams 
1980; Chiodo and Bunney 1983; White and Wang 1983 ; 
Hand et al. 1987; Chen et al. 1991). Interestingly, 
clozapine's mesolimbic selectivity is far more pronounced 
with chronic treatment than with acute (Gardner 1992a). 
Also of interest is the fact that only a subset of  the 
mesolimbic DA system is affected by clozapine the 
mesolimbic DA fibers terminating subcortically are 
blocked by clozapine while those terminating in the 
medial prefrontal cortex are not (Chen et al. 1991, 
1992a). This mesolimbically selective DA blockade in- 
duced by chronic clozapine appears to be depolarization 
blockade (Chiodo and Bunney 1985; Blaha and Lane 
1987; Chen et al. 1991). 
The extent to which clozapine's mesolimbic selectivity 
is duplicated by other clinically atypical antipsychotic 
drugs is not clear. The antipsychotics commonly referred 
to as "atypical" have widely differing preclinical and 
clinical profiles. Included are such "partially atypical" 
phenothiazines as thioridazine and mesoridazine, such 
"partially atypical" benzamides as sulpiride and remoxi- 
pride, and a number of other "partially atypical" com- 
pounds of widely varying chemical structures and recep- 
tor specificities. They do not constitute a homogeneous 
pharmacological class by any clinical or preclinical 
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criteria, and have each acquired the "atypical" label by 
exclusion rather than inclusion, i.e., by producing clinical 
effects or side effects different from those produced by 
classical neuroleptics (yet also often significantly dif- 
ferent from each other). None of these "partially atypi- 
cal" antipsychotics has been shown to fully duplicate 
clozapine's clinical profile. Yet, in spite of their ex- 
ceedingly heterogenous nature, a number of them par- 
tially share clozapine's mesolimbic selectivity (Gardner 
1992a). Unfortunately, the newest and most clozapine- 
like atypical drugs such as risperidone have not been well 
characterized in terms of mesolimbic/nigrostriatal selec- 
tivity. 
Second, the present data call into question the ade- 
quacy of invoking clozapine's anticholinergic potency to 
explain its mesolimbic selectivity. In the present study, 
the addition of the anticholinergic drug trihexyphenidyl 
to chronic haloperidol detracted from haloperidol's func- 
tional DA blockade in both the mesolimbic and nigro- 
striatal DA systems. These findings are at variance with 
those of Chiodo and Bunney (1985) and Lane and Blaha 
(1986), who found, using single-neuron electrophysiol0g- 
ical recording and in vivo voltammetry techniques, re- 
spectively, that the addition of trihexyphenidyl to chronic 
haloperidol detracted from haloperidol's functional DA 
blockade in only the nigrostriatal DA system, thus mim- 
icking clozapine's profile. It is not clear why the present 
data are at variance with those of Chiodo and Bunney 
(1985) and Lane and Blaha (1986), beyond the obvious 
and perhaps trivial explanation that we used a different 
laboratory approach to inferring anatomically selective 
functional DA blockade produced by antipsychotic drug 
treatment. On the other hand, the present data are clearly 
more congruent with the clinically observed phenomena 
that the addition of anticholinergic medication to neu- 
roleptic therapy not only detracts from nigrostriatal 
functional DA blockade (i.e., ameliorates neuroleptic- 
induced extrapyramidal side effects) but also detracts 
from mesolimbic functional DA blockade (i.e., decreases 
antipsychotic efficacy) (Singh and Kay 1979; Johnstone 
et al. 1983). 
In considering the present findings, the comparative 
anticholinergic profiles of clozapine and trihexyphenidyl 
should be noted. Using pharmacological approaches 
with selective antagonists, three muscarinic receptor 
subtypes, respectively designated M1, M2, and Ma, have 
been identified (Mitchelson 1988). By such pharmacolog- 
ical differentiation, both clozapine and trihexyphenidyl 
are relatively selective M1 antagonists. Using molecular 
biological approaches, five human muscarinic receptor 
subtypes - designated ml, m2, m3, m4, and m5 - have 
been cloned and shown to be expressed in brain and 
periphery (Bolden et al. 1992). It is believed that the first 
three of these gene products - the ml, m2, and m3 entities 
- correspond, respectively, to the pharmacologically iden- 
tified M1, M2, and M3 receptor subtypes (Bolden et al. 
1992). Both clozapine and trihexyphenidyl interact with all 
five cloned muscarinic receptor subtypes, but show high 
selectivity for the ml subtype (Bolden et al. 1992). They 
also show secondary selectivity for the m4 subtype. While 
not precisely duplicating clozapine's anticholinergic 
profile, trihexyphenidyl resembles clozapine reasonably 
well. In any event, slight differences in the antimuscarinic 
profiles of clozapine and trihexyphenidyl would appear 
irrelevant to any hypothesis for the differences between the 
present findings and those of Chiodo and Bunney (1985) 
and Lane and Blaha (1986), since the present study utilized 
the same reference anticholinergic (trihexyphenidyl), and 
precisely the same dose of trihexyphenidyl, as those work- 
ers. 
The present conclusion that clozapine's anticholiner- 
gic effects are not an adequate explanation for its 
mesolimbic selectivity and atypical clinical profile is sup- 
ported by previous work (Coward et al. 1989), including 
animal studies showing that combining haloperidol with 
atropine only partly mimics clozapine's pharmacological 
profile (Sayers et al. 1976). If clozapine's anticholinergic 
action does not explain its mesolimbic selectivity, what 
does? The possibilities are legion, since clozapine in- 
teracts with most if not all conventional neurotrans- 
mitters (Coward et al. 1989). Among the possibilities, 
however, current evidence suggests an important 
serotonin (5HT) component (Meltzer et al. 1989b; Chen 
et al. 1992b). Clozapine's antagonist potency is far more 
pronounced at 5HT receptors than at classically defined 
DA receptors. In addition, 5HT fibers innervate and 
powerfully modulate both the mesolimbic and nigro- 
striatal DA systems (Hetey and Drescher 1986; De Simon 
et al. 1987). However, the mesolimbic DA system receives 
a denser 5HT innervation than does the nigrostriatal DA 
system, and 5HT1B, 5HT2, and 5HT3 receptors are all 
more densely distributed in the mesolimbic DA system 
than the nigrostriatal DA system (Pazos and Palacios 
1985; Fischette et al. 1987; Waeber et al. 1988). Thus, the 
preferential mesolimbic distribution of 5HT afferents 
and receptors, coupled with 5HT's powerful modulatory 
regulation of forebrain DA function and clozapine's 
potent 5HT antagonism, may partly explain clozapine's 
preferential inhibition of the mesolimbic DA system 
(Chen et al. 1992b). 
Finally, the present data suggest that, in the absence 
of counteracting properties, the anticholinergic actions 
of antipsychotic drugs or drug combinations can be ex- 
pected to detract from antipsychotic efficacy. 
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